Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bertino

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2020
Phase IB Study of Osimertinib in Combination with Navitoclax in <i>EGFR</i>-mutant NSCLC Following Resistance to Initial <i>EGFR</i> Therapy (ETCTN 9903)Erin M Bertino, Ryan D Gentzler, Sarah Clifford, et al.
Investigational New Drugs|December 3, 2025
Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancerDwight H Owen, Ruohan Wu, Lai Wei, et al.
Clinical Lung Cancer|February 8, 2022
Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not ChemoimmunotherapyYizhen Guo, Lai Wei, Sandip H Patel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 20, 2021
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint InhibitorsAngel Qin, Songzhu Zhao, Abdul Miah, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2020
Phase IB Study of Osimertinib in Combination with Navitoclax in <i>EGFR</i>-mutant NSCLC Following Resistance to Initial <i>EGFR</i> Therapy (ETCTN 9903)Erin M Bertino, Ryan D Gentzler, Sarah Clifford, et al.
Investigational New Drugs|December 3, 2025
Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancerDwight H Owen, Ruohan Wu, Lai Wei, et al.
Clinical Lung Cancer|February 8, 2022
Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not ChemoimmunotherapyYizhen Guo, Lai Wei, Sandip H Patel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 20, 2021
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint InhibitorsAngel Qin, Songzhu Zhao, Abdul Miah, et al.
Pageof 7